Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 5/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.51 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1502039 | 1.00 | HTR4 (1.00) | HTR4CYP2C9PMP22NPSR1CYP1A2 | |
| Maleic Acid SCHEMBL2942174 | 0.95 | HTR4 (0.90) | HTR4CYP2C9PMP22NPSR1CYP1A2 | |
| SCHEMBL29626583 | 0.94 | HTR4 (1.00) | HTR4CYP2C9PMP22NPSR1CYP1A2 | |
| SCHEMBL7293994 | 0.94 | HTR4 (0.89) | HTR4CYP2C9PMP22NPSR1CYP1A2 | |
| SCHEMBL7300971 | 0.90 | HTR4 (0.81) | HTR4CYP2C9PMP22NPSR1CYP1A2 | |
| Maleic Acid SCHEMBL7295111 | 0.90 | HTR4 (0.81) | HTR4CYP2C9PMP22NPSR1CYP1A2 | |
| Fumaric Acid SCHEMBL7295114 | 0.90 | HTR4 (0.81) | HTR4CYP2C9PMP22NPSR1CYP1A2 | |
| SCHEMBL7300888 | 0.87 | HTR4 (0.77) | HTR4CYP2C9PMP22NPSR1CYP1A2 | |
| Hydrochloric Acid SCHEMBL7291228 | 0.86 | HTR4 (0.76) | HTR4CYP2C9PMP22NPSR1CYP1A2 | |
| SCHEMBL7294699 | 0.86 | HTR4 (0.76) | HTR4CYP2C9PMP22NPSR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114377131-A | Use of 5-hydroxytryptamine receptor subtypes 3 and 4 and antagonists thereof for treating post-cholecystectomy diarrhea | 上海市闵行区中心医院 | 2022-04-22 | — | — | CN | claimed |
| CN-122036690-A | Heteroaromatic ring compound, pharmaceutical composition and application thereof | 马应龙药业集团股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-3866800-B1 | NEW USES OF A 5-HT4 RECEPTOR AGONIST | SUVEN LIFE SCIENCES LTD (IN) | 2026-03-11 | — | — | EP | disclosed |
| US-12569471-B2 | Method of treatment of CNS disorders | SUPERNUS PHARMACEUTICALS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12285421-B2 | Uses of a 5-HT4 receptor agonist | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-04-29 | — | — | US | disclosed |
| US-20240293389-A1 | METHOD OF TREATING COGNITIVE DEFICITS ASSOCIATED WITH SCHIZOPHRENIA | SUVEN LIFE SCIENCES LIMITED (IN) | 2024-09-05 | — | — | US | disclosed |
| US-20240277690-A1 | NEW USES OF A 5-HT4 RECEPTOR AGONIST | SUVEN LIFE SCIENCES LIMITED (IN) | 2024-08-22 | — | — | US | disclosed |
| US-20230355589-A1 | METHOD OF TREATMENT OF CNS DISORDERS | SUPERNUS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230035892-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | FLAGSHIP PIONEERING, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20220323456-A1 | METHODS FOR TREATING, DIAGNOSING AND PROGNOSING A HAEMATOLOGICAL MALIGNANCY | INSTITUT DE RECERCA CONTRA LA LEUCÈMIA JOSEP CARRERAS (ES) | 2022-10-13 | — | — | US | disclosed |
| US-20220291237-A1 | Gene Expression Inflammatory Age and Its Uses | Edifice Health, Inc. (US) | 2022-09-15 | — | — | US | disclosed |
| US-20220274957-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-01 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-11337984-B2 | Methods for treating, diagnosing and prognosing a haematological malignancy | INSTITUT DE RECERCA CONTRA LA LEUCÉMIA JOSEP CARRERAS (ES) | 2022-05-24 | — | — | US | disclosed |
| CN-114377131-A | Use of 5-hydroxytryptamine receptor subtypes 3 and 4 and antagonists thereof for treating post-cholecystectomy diarrhea | 上海市闵行区中心医院 | 2022-04-22 | — | — | CN | disclosed |
| CN-114377131-A | Use of 5-hydroxytryptamine receptor subtypes 3 and 4 and antagonists thereof for treating post-cholecystectomy diarrhea | 上海市闵行区中心医院 | 2022-04-22 | — | — | CN | disclosed |
| US-11274158-B2 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-11254655-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12285421-B2 | Uses of a 5-HT4 receptor agonist | HTR4, HTR1A, HTR1D | HTR4 1/4885CYP2C9 928/4885PMP22 3805/4885 |
| US-20240277690-A1 | NEW USES OF A 5-HT4 RECEPTOR AGONIST | HTR4, HTR1A, HTR5A | HTR4 1/4885CYP2C9 892/4885PMP22 3810/4885 |
| US-11254655-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR1A, HTR5A | HTR4 1/4885CYP2C9 460/4885PMP22 4053/4885 |
| US-20220274957-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR1A, HTR5A | HTR4 1/4885CYP2C9 460/4885PMP22 4053/4885 |
| US-12569471-B2 | Method of treatment of CNS disorders | SLC6A2, SLC6A3, SLC18A2 | HTR4 28/4885CYP2C9 176/4885PMP22 471/4885 |
| US-20240293389-A1 | METHOD OF TREATING COGNITIVE DEFICITS ASSOCIATED WITH SCHIZOPHRENIA | HTR4, HTR1A, HTR1D | HTR4 1/4885CYP2C9 1169/4885PMP22 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.